BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12088871)

  • 1. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
    Sakamoto T; Eguchi H; Omoto Y; Ayabe T; Mori H; Hayashi S
    Mol Cell Endocrinol; 2002 Jun; 192(1-2):93-104. PubMed ID: 12088871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
    Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
    Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
    Shah YM; Rowan BG
    Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells.
    Wang Z; Kyo S; Maida Y; Takakura M; Tanaka M; Yatabe N; Kanaya T; Nakamura M; Koike K; Hisamoto K; Ohmichi M; Inoue M
    Oncogene; 2002 May; 21(22):3517-24. PubMed ID: 12032853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
    Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
    Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and regulation of Cyr61 in human breast cancer cell lines.
    Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R
    Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen and growth factor signaling pathway: basic approaches for clinical application.
    Hayashi S; Sakamoto T; Inoue A; Yoshida N; Omoto Y; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):433-42. PubMed ID: 14623541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
    Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
    Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
    J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells.
    Fujita T; Kobayashi Y; Wada O; Tateishi Y; Kitada L; Yamamoto Y; Takashima H; Murayama A; Yano T; Baba T; Kato S; Kawabe Y; Yanagisawa J
    J Biol Chem; 2003 Jul; 278(29):26704-14. PubMed ID: 12738788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
    Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
    Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
    Castro-Rivera E; Safe S
    J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
    Nichols M; Cheng P; Liu Y; Kanterewicz B; Hershberger PA; McCarty KS
    Breast Cancer Res Treat; 2010 Apr; 120(3):761-8. PubMed ID: 19526339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells.
    Singleton DW; Feng Y; Burd CJ; Khan SA
    Endocrinology; 2003 Jan; 144(1):121-8. PubMed ID: 12488337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
    Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
    J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
    Reiter R; Oh AS; Wellstein A; Riegel AT
    Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.